Welcome to our dedicated page for Mirati Therapeutics news (Ticker: MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeutics stock.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a commercial stage biotechnology company focused on pioneering breakthrough therapies to transform the lives of patients with cancer. Specializing in molecularly targeted and immuno-oncology combination therapies, Mirati is at the forefront of cancer treatment innovation. The core of Mirati's mission is to develop drug candidates that target genetic and epigenetic drivers of cancer. The company leverages a strategic approach that includes selecting patients whose tumors depend on specific genetic alterations and employing a highly accomplished leadership team in oncology precision medicine.
Mirati Therapeutics is advancing three primary drug candidates through clinical development for multiple oncology indications. Their flagship product, KRAZATI® (adagrasib), has shown promising results in treating non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation. Adagrasib offers potential best-in-class efficacy, particularly for patients with central nervous system metastases. Notably, the drug has been granted conditional marketing authorization by the UK's MHRA and the European Commission, highlighting its impactful role in current cancer treatment paradigms.
Mirati's innovative pipeline also includes MRTX1719, a PRMT5 inhibitor, and MRTX1133, a selective KRASG12D inhibitor, both of which are designed to address high unmet medical needs. The company recently completed an upsized public offering, extending its cash runway to support upcoming milestones.
In recent developments, Mirati announced that Laurie Stelzer, Chief Financial Officer, will depart the company in September 2023, with Aaron Ondrey stepping in as interim CFO. This transition comes at a pivotal time as Mirati continues to advance its clinical programs and prepare for potential new product launches.
With a relentless focus on patient outcomes, Mirati's vision is to unlock the science behind a life beyond cancer. The company continues to collaborate with global healthcare regulators and partners to ensure broad access to its groundbreaking therapies.
Mirati Therapeutics (NASDAQ: MRTX) announced promising clinical data for adagrasib, a potent KRASG12C inhibitor, demonstrating efficacy in patients with advanced solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC). The findings, published in the Journal of Clinical Oncology and presented at the ASCO Plenary Series in April 2023, indicate an overall objective response rate (ORR) of 35%, with 33% for PDAC and 42% for BTC. Adagrasib's safety profile aligns with prior studies on NSCLC and CRC. This Phase 2 data from the KRYSTAL-1 study highlights adagrasib’s potential as a monotherapy, especially given its recent inclusion in the NCCN guidelines for CNS cancers, signaling a pathway toward regulatory approval for additional indications.
Mirati Therapeutics (NASDAQ: MRTX) will announce first quarter 2023 financial results on May 9, 2023, at 4:30 p.m. ET. The event will include corporate updates and a review of financial results. Investors can listen to the call via a live webcast on Mirati's website or by dialing specific U.S. and international phone numbers.
Mirati is committed to developing therapies for cancer, focusing on unmet needs in areas like lung cancer. The company is advancing several promising therapeutics, including KRAZATI® (adagrasib), which targets genetic drivers of cancer. However, investors are reminded that forward-looking statements in the release carry risks and uncertainties, including those associated with COVID-19 and drug development processes.
FAQ
What is the market cap of Mirati Therapeutics (MRTX)?
What does Mirati Therapeutics specialize in?
What are the main drug candidates of Mirati Therapeutics?
What recent approvals has KRAZATI® received?
Who is the interim Chief Financial Officer of Mirati Therapeutics?
What is the focus of Mirati's drug development strategy?
Where can I find more information about Mirati's clinical trials?
How does Mirati's adagrasib (KRAZATI) differ from other cancer treatments?
What recent corporate updates has Mirati announced?
What is the mission of Mirati Therapeutics?
How can investors contact Mirati Therapeutics?
